

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

北斗嘉藥業股份有限公司
BAYTACARE PHARMACEUTICAL CO., LTD.*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8197)

VOLUNTARY ANNOUNCEMENT
IN RELATION TO
CRIMINAL COMPULSORY MEASURES BEING TAKEN AGAINST
FORMER CHAIRMAN WANG SHAOYAN'S FATHER (WANG YAN)
BY THE CHINESE PUBLIC SECURITY ORGANS

This announcement is made by Baytacare Pharmaceutical Co., Ltd.* (the “**Company**”) on a voluntary basis.

Reference is made to the announcements dated 26 April 2018, 27 April 2018, 30 April 2018, 9 July 2018, 14 September 2018, 26 September 2018, 21 December 2018 and 26 March 2019 of the Company in relation to, among others, the alleged misappropriation of the Company's funds by Mr. Wang Shaoyan (a former executive director of the Company and chairman of the board of directors of the Company (the “**Board**”)), Mr. Wang Shaoyan being criminally charged by the Company and being arrested by the Chinese public security organs, and his father, Mr. Wang Yan, being included in the investigation by the Chinese public security organs.

On 21 August 2019, the Board noted that the Chinese public security organs have taken criminal compulsory measures against Mr. Wang Yan to ensure the smooth proceeding of Mr. Wang Shaoyan's criminal case.

Trading in the shares of the Company has been suspended with effect from 9am on 27 September 2018, and will continue to be suspended until further notice.

By Order of the Board
Baytacare Pharmaceutical Co., Ltd.*
Executive Director
Cui Bingyan

Shenzhen, People's Republic of China, 26 August 2019

As at the date of this announcement, the executive Directors are Cui Bingyan, Fang Yao, Guo Aiqun and Zheng Chunyan; the non-executive Directors are Shi Peng and Cao Yang; and the independent non-executive Directors are Chen Youfang, Zhu Tianxiang and Zhao Xiaomei.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the website of GEM at www.hkgem.com for at least 7 days from the date of the publication and the Company’s website at www.baytacare.com from the date of this announcement.

**for identification purposes only*